About: HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study
Creator	Mohammad, · Bahmani, Bahareh Amini-Bayat, Zahra Nahid Bakhtiari, · Ranjbar, Mehdi Zarnani, · Amir-Hassan
Source	PMC
abstract	Cervical cancer is the second most common leading cause of women's death due to cancer worldwide, about 528,000 patients’ cases and 266,000 deaths per year, related to human papillomavirus (HPV). Peptide-based vaccines being safe, stable, and easy to produce have demonstrated great potential to develop therapeutic HPV vaccine. In this study, the major histocompatibility complex (MHC) class I, class II T cell epitopes of HPV16-E7 were predicted. Therefore, we designed a plan to find the most effective peptides to prompt appropriate immune responses. For this purpose, retrieving protein sequences, conserved region identification, phylogenic tree construction, T cell epitope prediction, epitope-predicted population coverage calculation, and molecular docking were performed consecutively and most effective immune response prompting peptides were selected. Based on different tools index, six CD8+ T cells and six CD4+ epitopes were chosen. This combination of 12 epitopes created a putative global vaccine with a 95.06% population coverage. These identified peptides can be employed further for peptide analysis and can be used as a peptide or poly-epitope candidates for therapeutic vaccine studies to treat HPV-associated cancers.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1007/s10989-020-10089-5
has license	no-cc
sha1sum (hex)	8e20e441064cfeb57326cc58ea789b113b7dbd0d
schema:url	https://doi.org/10.1007/s10989-020-10089-5
resource representing a document's title	HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study
has PubMed Central identifier	PMC7320846
schema:publication	Int J Pept Res Ther
resource representing a document's body	covid:8e20e441064cfeb57326cc58ea789b113b7dbd0d#body_text
is schema:about of	named entity 'peptides' named entity 'peptide' named entity 'employed' named entity 'CD8+ T cells' named entity 'common' named entity 'Protein' named entity 'Frequency' named entity 'STUDY' named entity 'ASSOCIATED' named entity 'PEPTIDE' named entity 'RETRIEVING' named entity 'ABOUT' named entity 'CD4' named entity '528' named entity 'TO PRODUCE' named entity 'CD8' named entity 'EPITOPES' named entity 'POLY' named entity 'ANALYSIS' covid:arg/8e20e441064cfeb57326cc58ea789b113b7dbd0d named entity 'class II' named entity 'T cell' named entity 'cancer' named entity 'selected' named entity 'produce' named entity 'therapeutic' named entity 'T cell' named entity 'created' named entity 'Study' named entity 'major histocompatibility complex' named entity 'immune response' named entity 'CD8+ T cells' named entity 'human papillomavirus' named entity 'peptides' named entity 'epitopes' named entity 'epitope' named entity 'class II' named entity 'phylogenic tree' named entity 'HPV-associated cancers' named entity 'vaccine' named entity 'MHC-I' named entity 'E6 and E7' named entity 'host cell' named entity 'peptide' named entity 'T-lymphocytes' named entity 'binding affinity' named entity 'ligand' named entity 'HPV16' named entity 'HLA' named entity 'vaccine' named entity 'E6 and E7' named entity 'E6 and E7' named entity 'allele' named entity 'n-glycosylation' named entity 'cervical cancer' named entity 'immunogenic' named entity 'animal models' named entity 'RNA' named entity 'FFT' named entity 'peptide' named entity 'clinical trials' named entity 'Iran' named entity 'HPV vaccine' named entity 'E6, and E7' named entity 'peptide' named entity 'Germany' named entity 'FOLD3' named entity 'HPV' named entity 'HLA' named entity 'recombinant' named entity 'HPV vaccines' named entity 'epitope' named entity 'epitope' named entity 'Sweden' named entity 'CD4+' named entity 'etiological' named entity 'killer cell' named entity 'FFT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software